WHO ICTRP trial
Effect of mirtazapine in treatment of proteinuria and blood sugar control
IRCT20160412027346N11 · Iranian Registry of Clinical Trials (IRCT) · Recruiting
Key facts
| Trial ID | IRCT20160412027346N11 |
|---|---|
| Public title | Effect of mirtazapine in treatment of proteinuria and blood sugar control |
| Scientific title | Evaluating the effect of mirtazapine on proteinuria and blood sugar control in patients with diabetic nephropathy |
| Primary sponsor | Shahid Beheshti University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Recruiting |
| Study type | interventional |
| Phase | 3 |
| Countries | Iran (Islamic Republic of) |
| Conditions | Diabetic nephropathy. Other specified diabetes mellitus with diabetic nephropathy;E13.21 |
| Interventions | Intervention 1: Intervention group: 46 patients in the intervention group will receive mirtazapine (manufactured by Tekajeh Pharmaceutical Company) at a dose of 15mg at night before bedtime. During the 90-day intervention period, each… |
| Registration date | May 11, 2025 |
| Target size | 96 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: